The Peptide YY pipeline drugs market research report outlays comprehensive information on the Peptide YY targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Peptide YY pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
The report also covers products from therapy areas such as Metabolic Disorders, Genetic Disorders, and Oncology which include the indications Obesity, Type 2 Diabetes, Prader-Willi Syndrome (PWS), Breast Cancer, and Pancreatic Cancer. It also reviews key players involved in Peptide YY targeted therapeutics development with respective active and dormant or discontinued products.
The Peptide YY pipeline targets constitutes close to five molecules. Out of which, approximately four molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase I, Preclinical, and Discovery stages are 1, 2, and 1 respectively. Similarly, the universities portfolio in Discovery comprises 1 molecule.
Peptide YY overview
Peptide YY is a gut peptide which inhibits exocrine pancreatic secretion, it has a vasoconstrictory action and inhibits jejunal and colonic mobility.
For a complete picture of Peptide YY’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.